Posts

FDA Places Partial Hold on Biohaven’s Epilepsy Drug After $350 Million Licensing Deal

on

SK Biopharmaceuticals Signs Up-to-$795 Million Biohaven Deal for Epilepsy Drug

on

Pfizer Has Already Made Its Biggest Deals, Bourla Says

on

Biohaven's BHV-7000 Ion Channel Drug Fails Phase 2 Trial in Major Depressive Disorder

on

FDA Rejects Biohaven's Ataxia Drug Vyglxia, Forcing Company to Cut Costs After Second Approval Failure

on

FDA Delays Decision on Biohaven's Troriluzole for Rare Disease, Plans Advisory Committee Review

on